Rhinitis, Cognition and Driving Performance

Maastricht University Medical Centre (MUMC)

Status: Completed

Conditions: Driving Ability; Cognition; Seasonal Allergic Rhinitis

Treatments: Drug: placebo; Drug: fluticasone furoate; Drug: cetirizine 10 mg

Study type: Interventional

Funder types: Other

Identifiers

NCT01318681

EPU-055

Details and patient eligibility

About

This study investigates the effects of Allergic Rhinitis (AR) on driving ability and memory functions. Our group has previously shown that patients suffering from AR symptoms perform less well on tasks requiring sustained attention compared to non symptomatic controls. Car driving is a typical behavior that is susceptible for changes in sustained attention and might therefore become worse under conditions when patients suffer from AR symptoms. We will compare the driving performance of untreated, symptomatic AR patients with the performance of symptomatic patients that have been treated with either a systemic AR medication (a pill) or a topical medication (nasal spray)

Enrollment: 22 patients

Sex: All

Ages: 21 to 45 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy volunteers known with Seasonal Allergic Rhinitis
• Experienced drivers holding a license
• 21- 45 years of age

Exclusion criteria

• Asthma or other chronic illness
• current psychoactive medication
• History of drug abuse

Trial design

22 participants in 4 patient groups, including a placebo group

Pollen provocation with systemic treatment

Experimental group

Description:

Subjects are treated with Cetirizine 10 mg after a nasal challenge with a pollen solution

Treatment:

Drug: cetirizine 10 mg

Pollen provocation with topical treatment

Experimental group

Description:

treatment with 25ug fluticasone furoate after a nasal pollen challenge

Treatment:

Drug: fluticasone furoate

placebo treatment after pollen challenge

Placebo Comparator group

Description:

Placebo treatment after a nasal challenge with pollen solution

Treatment:

Drug: placebo

control condition

No Intervention group

Description:

A placebo drug is administered after a sham nasal challenge with a pollen solution